Stay updated on Nivolumab Ipilimumab Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ipilimumab Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Nivolumab Ipilimumab Neuroendocrine Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now indicates that recruitment is closed, clarifying that no new participants will be enrolled. In addition, the navigation labels and the page revision label were updated to reflect the current version (v3.6.0).SummaryDifference0.5%

- Check15 days agoChange DetectedThe page now displays revision v3.5.5, replacing v3.5.4, signaling a minor backend/content management update. No study content or results are affected.SummaryDifference0.1%

- Check37 days agoChange DetectedThe revision label on the page was updated from v3.5.3 to v3.5.4, indicating a minor update to the page's documentation or metadata rather than substantive content changes.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page’s footer revision label has been updated from v3.5.2 to v3.5.3, reflecting a new site version rather than a change to the study’s content.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2, indicating a system update; no study content changes are indicated.SummaryDifference0.1%

- Check94 days agoChange DetectedAdded Carcinoid tumor to MeSH terms and included a Resources section for Genetic and Rare Diseases Information Center. Revision updated from v3.4.3 to v3.5.0.SummaryDifference0.2%

Stay in the know with updates to Nivolumab Ipilimumab Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ipilimumab Neuroendocrine Tumors Clinical Trial page.